{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:06:05Z","timestamp":1786118765724,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      A genome-wide association study identified that genetic variation in the twisted gastrulation protein homolog-1 gene (\n                      <jats:italic toggle=\"yes\">TWSG1<\/jats:italic>\n                      rs7242593) was linked to early clinical remission in ustekinumab-exposed patients in the UNITI clinical trials. We aimed to confirm if a single nucleotide variation (SNV) in the\n                      <jats:italic toggle=\"yes\">TWSG1<\/jats:italic>\n                      gene is associated with clinical remission in inflammatory bowel disease (IBD) patients on ustekinumab.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study was conducted in ustekinumab-treated IBD patients. Participants underwent screening for the\n                      <jats:italic toggle=\"yes\">TWSG1<\/jats:italic>\n                      SNV rs7242593 and were assessed for clinical disease remission by Harvey\u2013Bradshaw Index or partial Mayo score at 3 and 12 months. Ustekinumab dose and treatment duration were also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 125 IBD participants were included (wild-type genotype, CC,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u2005108; variant genotype, CT,\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2005=\u200517). Participants in the variant genotype group were more likely to achieve clinical remission at 3 months [odds ratio (OR): 23.11, 95% confidence interval (CI)\u2005=\u20053.92\u2013449.40, adjusted\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.0043] and at 12 months (OR\u2005=\u200517.75, 95%CI\u2005=\u20052.42\u2013381.0, adjusted\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.016) on standard ustekinumab dosing and less likely to discontinue therapy during the follow-up period (hazard ratio=4.20, 95% CI\u2005=\u20051.94\u20139.09,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u20050.02). For wild-type carriers, ustekinumab dose escalations were not associated with disease remission at any time.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">TWSG1<\/jats:italic>\n                      SNV was associated with early and persistent clinical remission in ustekinumab-exposed IBD patients. Wild-type carriers who did not achieve remission were not rescued with high-dose treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/fpc.0000000000000602","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:00:09Z","timestamp":1776758409000},"page":"157-162","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["TWSG1 variation identifies a ustekinumab-response phenotype in patients with inflammatory bowel disease"],"prefix":"10.1097","volume":"36","author":[{"given":"Mohammed","family":"Alkhalifa","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gio R.","family":"Dela Cruz","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Ponich","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Gregor","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Yan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Khanna","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"McIntosh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie D.","family":"Beaton","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, Department of Medicine"},{"name":"Department of Physiology and Pharmacology, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aze","family":"Wilson","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine"},{"name":"Division of Clinical Pharmacology and Toxicology, Department of Medicine"},{"name":"Department of Physiology and Pharmacology, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"R1-20260528","doi-asserted-by":"crossref","first-page":"8816041","DOI":"10.1155\/2021\/8816041","article-title":"Th17 cells in inflammatory bowel disease: cytokines, plasticity, and therapies.","volume":"2021","author":"Zhao","year":"2021","journal-title":"J Immunol Res"},{"key":"R2-20260528","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","article-title":"Targeting the interleukin 23 pathway in inflammatory bowel disease.","volume":"168","author":"Bourgonje","year":"2025","journal-title":"Gastroenterology"},{"key":"R3-20260528","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1007\/s10620-023-08014-z","article-title":"Efficacy and safety of IL-12\/23 and IL-23 inhibitors for Crohn\u2019s disease: systematic review and meta-analysis.","volume":"68","author":"Vuyyuru","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"Supplement_2","key":"R4-20260528","doi-asserted-by":"crossref","first-page":"ii54","DOI":"10.1093\/ecco-jcc\/jjac007","article-title":"IL-23 blockade in anti-TNF refractory IBD: from mechanisms to clinical reality.","volume":"16","author":"Atreya","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R5-20260528","doi-asserted-by":"crossref","first-page":"S585","DOI":"10.1016\/S0016-5085(17)32105-4","article-title":"Long-term efficacy and safety of ustekinumab for Crohn\u2019s disease: results from IM-UNITI long-term extension through two years.","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterology"},{"key":"R6-20260528","doi-asserted-by":"crossref","first-page":"910","DOI":"10.14309\/ajg.0000000000002621","article-title":"Efficacy and safety of ustekinumab for ulcerative colitis through 4 years: final results of the UNIFI long-term maintenance study.","volume":"119","author":"Afif","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"R7-20260528","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cgh.2021.02.025","article-title":"Five-year efficacy and safety of ustekinumab treatment in Crohn\u2019s disease: the IM-UNITI trial.","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R8-20260528","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma.","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"R9-20260528","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4046\/trd.2023.0103","article-title":"Tailored biologics selection in severe asthma.","volume":"87","author":"Kim","year":"2024","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"R10-20260528","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11882-017-0678-1","article-title":"Phenotype-driven therapeutics in severe asthma.","volume":"17","author":"Opina","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"key":"R11-20260528","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1093\/ecco-jcc\/jjx002.083","article-title":"DOP046 genome-wide association study of baseline disease characteristics and response to ustekinumab in moderate to severe Crohn\u2019s disease.","volume":"11","author":"Hart","year":"2017","journal-title":"J Crohns Colitis"},{"key":"R12-20260528","doi-asserted-by":"crossref","first-page":"12755","DOI":"10.3390\/ijms232112755","article-title":"Multifaceted functions of TWSG1: from embryogenesis to cancer development.","volume":"23","author":"Suzuki","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R13-20260528","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"R14-20260528","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity.","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"R15-20260528","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.31557\/APJCP.2025.26.4.1129","article-title":"The role of twisted gastrulation 1 (TWSG1) gene in TGF-\u03b2 signaling linked to cancer: a comprehensive review.","volume":"26","author":"Kumar","year":"2025","journal-title":"Asian Pac J Cancer Prev"},{"key":"R16-20260528","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00535-017-1350-1","article-title":"TGF-\u03b2 in inflammatory bowel disease: a key regulator of immune cells, epithelium, and the intestinal microbiota.","volume":"52","author":"Ihara","year":"2017","journal-title":"J Gastroenterol"},{"key":"R17-20260528","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource.","volume":"18","author":"Kapizioni","year":"2023","journal-title":"J Crohns Colitis"},{"key":"R19-20260528","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1053\/j.gastro.2015.06.002","article-title":"Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease.","volume":"149","author":"Coenen","year":"2015","journal-title":"Gastroenterology"},{"key":"R20-20260528","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/apt.14483","article-title":"HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.","volume":"47","author":"Wilson","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R21-20260528","doi-asserted-by":"crossref","first-page":"e00332","DOI":"10.14309\/ctg.0000000000000332","article-title":"Pretreatment HLADQA1-HLADRB1 testing for the prevention of azathioprine-induced pancreatitis in inflammatory bowel disease: a prospective cohort study.","volume":"12","author":"Wilson","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"R22-20260528","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/ng.3093","article-title":"HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants.","volume":"46","author":"Heap","year":"2014","journal-title":"Nat Genet"},{"key":"R23-20260528","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/apt.15563","article-title":"HLADQA1*05 genotype predicts anti-drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease.","volume":"51","author":"Wilson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R24-20260528","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.gastro.2019.09.041","article-title":"HLA-DQA1*05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn\u2019s disease.","volume":"158","author":"Sazonovs","year":"2020","journal-title":"Gastroenterology"},{"key":"R25-20260528","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cgh.2023.08.041","article-title":"HLADQA1*05G>A genetic screening promotes the safe delivery of combination therapy in inflammatory bowel disease.","volume":"22","author":"Wilson","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R26-20260528","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn\u2019s disease (PROFILE): a multicentre, open-label randomised controlled trial.","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R27-20260528","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.cgh.2021.10.002","article-title":"Effectiveness of reinduction and\/or dose escalation of ustekinumab in Crohn\u2019s disease: a systematic review and meta-analysis.","volume":"20","author":"Meserve","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:55:34Z","timestamp":1786035334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000602","relation":{},"ISSN":["1744-6872","1744-6880"],"issn-type":[{"value":"1744-6872","type":"print"},{"value":"1744-6880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]}}}